Bone Marrow DNA Sequencing Predicts Acute Lymphoblastic Leukemia Relapse After Tisagenlecleucel
Findings from the phase 2 ENSIGN and ELIANA studies suggest DNA sequencing predicts ALL relapse.
AUTO1 CAR T Therapy Improves EFS in Relapsed/Refractory Acute Lymphoblastic Leukemia
Event-free survival was 68.3% at 6 months, 48.3% at 12 months, and 48.3% at 24 months in patients treated with AUTO1.
Allogeneic HSCT Significantly Improves EF Survival in Patients With MDS
Patients with MDS treated with alloHSCT and 5-aza had significant improvements in event-free survival compared to 5-aza treatment alone.
HuCART19 Efficacious and Durable in B-cell Acute Lymphoblastic Leukemia
huCART19 is designed to yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
2 Clarke Drive Cranbury, NJ 08512